# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
Evercore ISI Group analyst Cory Kasimov initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating...
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature...
Morgan Stanley analyst Matthew Harrison maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the pri...
Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price targ...
Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target ...